<![CDATA[CALR Mutation–Directed Agents and Targeted Therapies Represent Key Research Avenue in MPN Management]]>
Although JAK inhibitors have become mainstays across myeloproliferative neoplasm (MPN) treatment paradigms, the integration of targeted therapies for these patient populations could drive further progress in disease modification and help improve long-term …